Helicobacter Pylori Infection Clinical Trial
Official title:
Helicobacter Pylori Infection in Renal Transplant Patients
Upper gastrointestinal (GI) symptoms are frequent in organ transplant recipients. Peptic ulcers and related pathologies such as gastritis and duodenitis are known to occur with increased frequency (20-60%) and severity in renal transplant recipients. The frequency of severe complications is about 10% among transplant recipients and 10% of those might prove fatal As kidney transplant recipients have to take immunosuppressive drugs for a lifetime and because these drugs have many side effects that may not be differentiated from H. pylori infection Thus, in order to reduce the use of medications and subsequently to reduce the drug interactions ,proper detection and management of H pylori infection in those patients is preferred.
The prevalence of HP colonization is about 30% in the United States and other developed
countries as opposed to more than 80% in most developing countries.
Essentially, all HP-colonized persons have gastric inflammation, but this condition in itself
is asymptomatic.
Upper gastrointestinal (GI) symptoms are frequent in organ transplant recipients. Peptic
ulcers and related pathologies such as gastritis and duodenitis are known to occur with
increased frequency (20-60%) and severity in renal transplant recipients. The frequency of
severe complications is about 10% among transplant recipients and 10% of those might prove
fatal.
GI complications might require dose reduction or the discontinuation of some of the
immunosuppressive medications, affecting graft survival.
Considering the strong body of evidence supporting causal effects of HP infections on the
development of peptic ulcers and gastric malignancies, the argumented rate of
gastrointestinal complaints may bebattributed to increased HP infection rate among this
population.
Few studies have investigated the prevalence of HP infection; about 30% to 40% of renal
transplant recipients shown HP colonization of the stomach There are conflicting data about
the prevalence of H pylori infection in renal transplant recipients. Most of these studies
used anti HP IgG to diagnose H. pylori infection that lack consistent sensitivity and
specificity.
Nasri and his colleagues in 2013 concluded significant positive association of serum H.
Pylori IgG antibody titer with renal function in renal transplant patient.
As kidney transplant recipients have to take immunosuppressive drugs for a lifetime and
because these drugs have many side effects that may not be differentiated from H. pylori
infection Thus, in order to reduce the use of medications and subsequently to reduce the drug
interactions ,proper detection and management of H pylori infection in those patients is
preferred.
There are few studies have investigated the prevalence of HP infection; about 30% to 40% of
renal transplant recipients shown HP colonization of the stomach. There are conflicting data
about the prevalence of H pylori infection in renal transplant recipients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05061732 -
Helicobacter Pylori Eradication and Follow-up
|
Phase 4 | |
Completed |
NCT03779074 -
Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies
|
Phase 3 | |
Completed |
NCT06076681 -
A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules
|
Phase 1/Phase 2 | |
Recruiting |
NCT05329636 -
Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05065138 -
Comparison of Helicobacter Pylori Eradication Effect Before and After Training of Gastroenterologists
|
N/A | |
Completed |
NCT05049902 -
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication
|
Phase 4 | |
Not yet recruiting |
NCT06200779 -
Tailored vs. Empirical Helicobacter Pylori Infection Treatment
|
Phase 4 | |
Not yet recruiting |
NCT06037122 -
Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication
|
||
Completed |
NCT04617613 -
Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait
|
Phase 4 | |
Withdrawn |
NCT02552641 -
Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole
|
Phase 4 | |
Completed |
NCT02557932 -
Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication
|
Phase 3 | |
Completed |
NCT02873247 -
Standardize Communication With General Practitioner & Patient for Improved Eradication of Helicobacter Pylori
|
||
Recruiting |
NCT02249546 -
Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection
|
Phase 4 | |
Completed |
NCT01933659 -
Anti-H. Pylori Effect of Deep See Water
|
Phase 3 | |
Unknown status |
NCT01464060 -
14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication
|
Phase 4 | |
Completed |
NCT00841490 -
Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults
|
N/A | |
Recruiting |
NCT05549115 -
Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection
|
N/A | |
Recruiting |
NCT05728424 -
One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL
|
Phase 3 | |
Recruiting |
NCT05997433 -
Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori(SHARE2302)
|
N/A | |
Completed |
NCT04708405 -
The Relationship Between Helicobacter Pylori Infection and Inflammatory Bowel Diseases: A Real-life Observation
|